BF-B — Brown-Forman Corporation

Sentiment as of 2026-09-13 is neutral-to-cautious, matching the Street's consensus 'Hold' (24 Holds, 5 Buys, 7 Sells). The September 2, 2026 Q1 FY27 print was a mixed bag: net sales of $911M fell 1% YoY and slightly missed (~$915-918M expected), but EPS of $0.38 beat ($0.37 expected), gross margin expanded to ~60.2%, and management reaffirmed full-year guidance toward the favorable end of its range. Wall Street targets are genuinely split (UBS at $30 citing a deep valuation discount versus JPMorgan 'Underweight' at $25 on weak developed-market volumes), which is why the stock has drifted -6.09% over the past month without collapsing. Two overhangs add uncertainty rather than clarity: the July 2026 unsolicited acquisition proposal from Sazerac, and the pending retirement of CEO Lawson Whiting.

The three-year trend is stabilization at a lower level, not accelerating growth. Quarterly revenue has drifted from $1,107M (Oct-2023) to $911M (Jul-2026), but the YoY path is uneven rather than a straight decline: -5.4% in the Jan-2026 quarter ($1,036M vs $1,095M), then +2.0% in Apr-2026 ($912M vs $894M), +2.0% in Jan-2026 vs prior year, and -1.4% in the Jul-2026 quarter ($911M vs $924M). Margins are the better story: gross margin has run 57-63% and expanded YoY in the most recent quarter to ~60.2% from ~59.7%, with TTM operating margin a healthy 28.6% and net margin 18.4%. The EPS series (0.50, 0.60, 0.56, 0.41, 0.55, 0.57, 0.31, 0.36, 0.47, 0.56, 0.12, 0.38) shows one clear outlier: the Apr-2026 quarter earned $54M net income on $216M operating income — a ~$115M below-the-line hit that is almost certainly a one-off item and is what dragged TTM EPS to $1.572. Ex that quarter, underlying earnings are roughly flat to modestly up, and Q1 FY27 net income rose 3.5% YoY ($176M vs $170M) with FCF of $161M. Verdict: cyclical trough with early stabilization signals, not (yet) an inflection.

Cheap versus its own history, fair-to-slightly-cheap in absolute terms as of 2026-09-13. The trailing P/E of 17.0x is a ~38% discount to the 5-year average of 27.3x, and P/S of 3.12x is a ~45% discount to the 5-year average of 5.65x — levels not seen since the financial crisis era. The PEG ratio of -1.219 is mathematically meaningless here (negative growth denominator), so ignore it. Forward math is more informative: FY27 consensus EPS of $1.707 puts the stock at ~15.4x forward earnings, with a 3.36% dividend yield covered roughly 2.2x by TTM free cash flow (~$925M, a ~7.6% FCF yield on a $12.2B market cap). EV/EBITDA of ~13.3x is not distressed and sits near global spirits peers (Diageo/Pernod in the mid-to-high teens P/E), so this is a de-rating to a new normal baseline more than an obvious mispricing. The discount is real but largely earned by low growth.

The market has already repriced BF-B from a premium compounder multiple (27x) to a mature-staples multiple (17x trailing / 15.4x forward), so the volume-decline narrative is substantially in the price — that is the bullish case for patient money. The catch: the forward number itself is optimistic. With Q1 FY27 EPS at $0.38, hitting the $1.707 full-year estimate requires the remaining three quarters to deliver roughly $1.33 versus $1.15 in the comparable prior-year quarters — about +15% YoY — off a base where revenue is declining. If US takeaway and European volumes do not firm into the holiday season, the 'cheap' forward P/E gets revised higher rather than the price getting revised lower. Buyers here are underwriting a second-half FY27 volume/margin recovery plus a one-off-charge-free year; sellers are underwriting structural volume decline. Watch the December print for which one is winning.

Weak but not washed out as of 2026-09-13. RSI(14) was 41.22 — below neutral, above oversold. The stock was 4.28% below its 20-day SMA, 3.51% below its 50-day, and 3.66% below its 200-day, with -6.09% over one month and -1.91% over one week, even though it is still +11.62% over six months. Those three moving averages cluster tightly around $27.17-$27.39 (implied), so the $27.2-$27.4 zone is the line in the sand: a reclaim would signal the six-month basing pattern is intact, while continued failure there keeps the stock range-bound between $22.61 and $31.92 with a downward bias. This is not an oversold bounce setup; it is a 'wait for a higher low or a reclaim of the 200-day' setup. Entry-timing implication: scale in on weakness near the low-to-mid $20s or wait for confirmation above ~$27.3.

• Post-pandemic spirits demand normalization: volumes are contracting across developed markets as consumers trade down and pull back on discretionary on-premise spend, with US takeaway only gradually recovering from a soft winter trough.
• RTD (ready-to-drink) is the one genuinely growing spirits category and is acting as Brown-Forman's top-line buffer via Jack Daniel's Tennessee Blackberry (30+ markets) and New Mix innovation.
• Developed international consumer retrenchment and FX: European and other developed-market weakness dragged organic volumes and helped create the gap between reported operating income (-7% YoY in Q1 FY27) and the ~4% organic operating income gain management cited.
• Defensive sector rotation: with a 0.331 beta and a 3.36% dividend, BF-B periodically catches safety-driven inflows during macro volatility, oil spikes and inflation anxiety, which is part of why the stock is +11.62% over six months despite flat fundamentals.
• Rate and regulatory sensitivity: a bond-proxy staples profile makes the shares sensitive to rate moves, while excise/regulatory pressure and health-and-moderation trends (including GLP-1-driven reduced alcohol consumption) weigh on the long-term volume outlook for the whole category.

• Q2 FY27 earnings in early December 2026 (provisionally Dec 3-9): holiday-season takeaway in the US and Europe, plus confirmation or revision of the reaffirmed FY27 guidance and the ambitious ~+15% YoY implied EPS run-rate for the remaining three quarters.
• CEO succession: formal announcement and timeline for replacing retiring CEO Lawson Whiting; the incoming CEO's capital-allocation stance (brand reinvestment vs. cost discipline vs. M&A) is a genuine strategy fork.
• Any renewal or resolution of the July 2026 unsolicited Sazerac acquisition proposal — a live (if informal) takeover interest that gives the stock a strategic floor it did not have a year ago.
• Innovation/RTD execution: whether Jack Daniel's Tennessee Blackberry, New Mix and the revived Kentucky Boy bourbon can offset core whiskey and tequila volume declines, plus whether gross margin holds at ~60%.
• Multiple re-rating potential: at 15.4x forward earnings versus a 5-year average of 27.3x trailing, even a partial re-rating plus modest earnings growth would produce a solid total return — but only if volume growth stops going backwards.

• The decline may be structural, not cyclical. Moderation, GLP-1 usage and younger consumers drinking less could make the current 17x multiple deserved rather than a discount, in which case 'cheap vs. its own history' is a value trap.
• Earnings-quality/fresh-charge risk: the Apr-2026 quarter showed $54M net income against $216M operating income — a large below-the-line hit. If similar charges, impairments or write-downs recur, the $1.572 trailing EPS and the 15.4x forward P/E both understate how expensive the stock really is.
• Guidance execution risk: FY27 consensus EPS of $1.707 requires ~15% YoY growth across the remaining three quarters while revenue is flat-to-down; a single soft holiday quarter likely forces estimate cuts.
• Leadership/governance risk: CEO transition plus a family-controlled dual-class A/B structure during a demand downturn creates execution and capital-allocation uncertainty.
• International and FX risk: European and developed-market consumer weakness and currency translation have already created a roughly 11-point gap between reported and organic operating performance in the latest quarter.
• Sector de-rating risk: at ~13.3x EV/EBITDA, BF-B is not obviously cheap versus spirits peers on that metric; further peer compression would cap upside regardless of BF-B's own execution.

Brown-Forman is a high-quality, cash-generative, low-beta franchise with a fortress balance sheet (current ratio 3.26x, debt/equity 0.62, ~$925M TTM free cash flow) and a well-covered 3.36% dividend, trading at 17x trailing and ~15.4x forward earnings versus a 27.3x five-year average — but the discount is earned, not gifted. Revenue is flat-to-down, developed-market volumes are contracting, and the forward EPS number embeds a ~15% YoY second-half recovery that is not visible in the top line. At $26 the stock is a reasonable income/value holding with a favorable risk/reward skew versus its own history and a live takeover-flavored floor, but it is not a compelling growth story and there is no technical or fundamental confirmation of a turn yet.

I applied a justified 17.0x forward P/E to next-FY consensus EPS of $1.707, giving $29.02 (rounded to $29.00). The 17x multiple is deliberately below the stock's 5-year average of 27.3x trailing — reflecting a structurally slower growth profile than the 2019-2023 premium era — but above the current 15.4x forward, because Jack Daniel's brand strength, a 28.6% operating margin, a 13.3% ROIC and a fortress balance sheet warrant a modest premium to the global spirits peer group. Cross-checking with a 13x forward EV/EBITDA on ~$1.19B of forward EBITDA less ~$2.1B net debt implies roughly $28.70 of equity value per share, which corroborates the P/E-based figure within ~1%.